BridgeBio Pharma, Inc. (BBIO) News & EventsBBIONews & EventsBridgeBio Pharma, Inc.

BridgeBio Pharma Presents New Analyses of Attruby Study at ESC 2026

BridgeBio Pharma presented new analyses from the Phase 3 ATTRibute-CM study of Attruby in transthyretin amyloid cardiomyopathy, ATTR-CM, including the cardiac magnetic resonance imaging, CMR, substudy and the open-label extension, OLE, at the European Society of Cardiology, ESC, Congress 2026. Acoramidis is the only selective small molecule, orally administered, near-complete transthyretin, TTR, stabilizer. The study found: In a completer analysis, clinically meaningful improvement from baseline in left ventricular systolic function was observed in 54% of acoramidis-treated patients versus 20% of placebo-treated patients at Month 30, and in 53% of continuous-acoramidis patients at Month 42; For context, only 26% of completers in an independent natural history cohort demonstrated improved LV systolic function by Month 24 - approximately half the rate observed with acoramidis, suggesting that this magnitude of improvement falls outside the expected natural course of disease; In a conservative analysis, long-term acoramidis treatment was associated with clinically meaningful improvement from baseline in LV systolic function in approximately one-third of patients over 30-42 months. Improvement was observed in 34% of acoramidis-treated patients versus 9% of placebo-treated patients at Month 30 and in 30% of continuous-acoramidis patients at Month 42; In addition, 46% of patients receiving continuous acoramidis demonstrated improvement from baseline in LV mass index at Month 42, providing evidence of favorable structural remodeling; These results provided sufficient evidence for BridgeBio to recently dose its first participant in ASCEND-ATTR, a Phase 3b/4 study designed to determine if acoramidis is associated with sustained improvement in myocardial structural disease progression, function and amyloid burden

BridgeBio Pharma Doses First Participant in ASCEND-ATTR Study

BridgeBio Pharma announced that the first participant has been dosed in ASCEND-ATTR, a Phase 3b/4 study designed to further characterize the long-term effects of acoramidis on the improvement of cardiac structure, function, and amyloid burden in individuals with transthyretin amyloid cardiomyopathy.

BridgeBio Pharma Launches Secondary Offering of 5M Shares

BridgeBio Pharma announced the launch of a secondary public offering of 5M shares of its common stock by the selling stockholder KKR Genetic Disorder. The company is not selling any shares and will not receive any of the proceeds of the offering. William Blair, Goldman Sachs & Co. and KKR are acting as joint book-running managers for the proposed offering.